BR112017011642A2 - composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+. - Google Patents

composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.

Info

Publication number
BR112017011642A2
BR112017011642A2 BR112017011642A BR112017011642A BR112017011642A2 BR 112017011642 A2 BR112017011642 A2 BR 112017011642A2 BR 112017011642 A BR112017011642 A BR 112017011642A BR 112017011642 A BR112017011642 A BR 112017011642A BR 112017011642 A2 BR112017011642 A2 BR 112017011642A2
Authority
BR
Brazil
Prior art keywords
nad
treating
benefits
disease
compound
Prior art date
Application number
BR112017011642A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Henke Brad
Schulte Christie
Haffner Curt
Norman Deaton David
PREUGSCHAT Frank
David Becherer J
Cadilla Rodolfo
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112017011642A2 publication Critical patent/BR112017011642A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017011642A 2014-12-03 2015-11-19 composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+. BR112017011642A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
BR112017011642A2 true BR112017011642A2 (pt) 2018-03-06

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011642A BR112017011642A2 (pt) 2014-12-03 2015-11-19 composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.

Country Status (11)

Country Link
US (1) US9840496B2 (https=)
EP (1) EP3227275B1 (https=)
JP (1) JP6550132B2 (https=)
KR (1) KR20170090478A (https=)
CN (1) CN107428733A (https=)
AU (1) AU2015356721B2 (https=)
BR (1) BR112017011642A2 (https=)
CA (1) CA2969178A1 (https=)
ES (1) ES2717260T3 (https=)
RU (1) RU2017121002A (https=)
WO (1) WO2016087975A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7516047B2 (ja) * 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
MX2022001019A (es) * 2019-07-31 2022-02-22 Ribon Therapeutics Inc Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
US20230025807A1 (en) * 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
CN115697985B (zh) 2020-04-07 2025-01-21 米托布里奇公司 Cd38抑制剂
CA3195121A1 (en) * 2020-10-09 2022-04-14 Robert A. Volkmann Heteroaryl amide inhibitors of cd38
HRP20251111T1 (hr) 2021-01-29 2025-11-21 Boehringer Ingelheim International Gmbh Azakinolini kao inhibitori cd38
WO2022228496A1 (en) * 2021-04-30 2022-11-03 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
TW202310835A (zh) * 2021-07-12 2023-03-16 美商胞質動力學公司 Ｃｄ３８調節劑及其使用方法
WO2024254396A1 (en) * 2023-06-07 2024-12-12 Flagship Pioneering Innovations, Vi, Llc Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433840C (en) * 2001-01-04 2010-05-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
WO2010025235A1 (en) * 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Also Published As

Publication number Publication date
RU2017121002A3 (https=) 2019-03-15
RU2017121002A (ru) 2019-01-11
AU2015356721B2 (en) 2018-03-15
US20170260164A1 (en) 2017-09-14
WO2016087975A1 (en) 2016-06-09
JP2018501215A (ja) 2018-01-18
EP3227275A1 (en) 2017-10-11
EP3227275B1 (en) 2019-01-02
ES2717260T3 (es) 2019-06-20
US9840496B2 (en) 2017-12-12
CA2969178A1 (en) 2016-06-09
CN107428733A (zh) 2017-12-01
AU2015356721A1 (en) 2017-06-08
KR20170090478A (ko) 2017-08-07
JP6550132B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
BR112018004620A2 (pt) moduladores da expressão de kras
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
CL2015003731A1 (es) Inhibidores de bromodominios
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX2017003516A (es) Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc).
MX389228B (es) Composiciones para tratar el cabello.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
PH12016502062B1 (en) Compositions and methods for modulating complement factor b expression
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201790398A1 (ru) Способы лечения заболевания печени
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
NZ748769A (en) Nitroxyl donors with improved therapeutic index
MX389591B (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112014026160A2 (pt) métodos para tratar intolerância à lactose
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX388409B (es) Composiciones y metodos para tratar canceres.
MX2019004321A (es) Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired